STAT+: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease
STAT
DECEMBER 12, 2023
The news comes as researchers are still processing the Food and Drug Administration’s landmark approval of two cutting-edge sickle cell therapies, one made by Vertex Pharmaceuticals and CRISPR Therapeutics and the other by Bluebird Bio. These drugs have price tags of $2.2 million and $3.1 million, respectively.
Let's personalize your content